Operational definition of precipitated opioid withdrawal

被引:13
作者
Dunn, Kelly E. [1 ]
Bird, H. Elizabeth [1 ]
Bergeria, Cecilia L. [1 ]
Ware, Orrin D. [1 ,2 ]
Strain, Eric C. [1 ]
Huhn, Andrew S. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[2] Univ North Carolina Chapel Hill, Sch Social Work, Chapel Hill, NC USA
来源
FRONTIERS IN PSYCHIATRY | 2023年 / 14卷
关键词
opioids; opioid use disorder; fentanyl; buprenorphine; precipitated; withdrawal; heroin; naloxone;
D O I
10.3389/fpsyt.2023.1141980
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
BackgroundOpioid withdrawal can be expressed as both a spontaneous and precipitated syndrome. Although spontaneous withdrawal is well-characterized, there is no operational definition of precipitated opioid withdrawal. MethodsPeople (N = 106) with opioid use disorder maintained on morphine received 0.4 mg intramuscular naloxone and completed self-report (Subjective Opiate Withdrawal Scale, SOWS), visual analog scale (VAS), Bad Effects and Sick, and observer ratings (Clinical Opiate Withdrawal Scale, COWS). Time to peak severity and minimal clinically important difference (MCID) in withdrawal severity were calculated. Principal component analysis (PCA) during peak severity were conducted and analyzed with repeated measures analyses of variance (ANOVA). ResultsWithin 60 min, 89% of people reported peak SOWS ratings and 90% of people had peak COWS scores as made by raters. Self-reported signs of eyes tearing, yawning, nose running, perspiring, hot flashes, and observed changes in pupil diameter and rhinorrhea/lacrimation were uniquely associated with precipitated withdrawal. VAS ratings of Bad Effect and Sick served as statistically significant severity categories (0, 1-40, 41-80, and 81-100) for MCID evaluations and revealed participants' identification with an increase of 10 [SOWS; 15% maximum percent effect (MPE)] and 6 (COWS; 12% MPE) points as meaningful shifts in withdrawal severity indicative of precipitated withdrawal. ConclusionData suggested that a change of 10 (15% MPE) and 6 (12% MPE) points on the SOWS and COWS, respectively, that occurred within 60 min of antagonist administration was identified by participants as a clinically meaningful increase in symptom severity. These data provide a method to begin examining precipitated opioid withdrawal.
引用
收藏
页数:8
相关论文
共 15 条
  • [1] Microinduction of Buprenorphine/Naloxone: A Review of the Literature
    Ahmed, Saeed
    Bhivandkar, Siddhi
    Lonergan, Brady B.
    Suzuki, Joji
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (04) : 305 - 315
  • [2] Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone
    Antoine, Denis
    Huhn, Andrew S.
    Strain, Eric C.
    Turner, Gavin
    Jardot, Jasmyne
    Hammond, Alexis S.
    Dunn, Kelly E.
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (01) : 83 - 87
  • [3] High-dose buprenorphine for treatment of high potency opioid use disorder
    Danilewitz, Marlon
    McLean, Mark
    [J]. DRUG AND ALCOHOL REVIEW, 2020, 39 (02) : 135 - 137
  • [4] Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome
    Dunn, Kelly
    Bergeria, Cecilia
    Huhn, Andrew S.
    Strain, Eric C.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2020, 215
  • [5] Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence
    Dunn, Kelly E.
    Huhn, Andrew S.
    Bergeria, Cecilia L.
    Gipson, Cassandra D.
    Weerts, Elise M.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 371 (02) : 422 - 452
  • [6] Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes
    Dunn, Kelly E.
    Weerts, Elise M.
    Huhn, Andrew S.
    Schroeder, Jennifer R.
    Tompkins, David Andrew
    Bigelow, George E.
    Strain, Eric C.
    [J]. ADDICTION BIOLOGY, 2020, 25 (01)
  • [7] Efficacy of Tramadol Extended-Release for Opioid Withdrawal A Randomized Clinical Trial
    Dunn, Kelly E.
    Tompkins, D. Andrew
    Bigelow, George E.
    Strain, Eric C.
    [J]. JAMA PSYCHIATRY, 2017, 74 (09) : 885 - 893
  • [8] HANDELSMAN L, 1987, AM J DRUG ALCOHOL AB, V13, P293, DOI 10.3109/00952998709001515
  • [9] High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
    Herring, Andrew A.
    Vosooghi, Aidan A.
    Luftig, Joshua
    Anderson, Erik S.
    Zhao, Xiwen
    Dziura, James
    Hawk, Kathryn F.
    McCormack, Ryan P.
    Saxon, Andrew
    D'Onofrio, Gail
    [J]. JAMA NETWORK OPEN, 2021, 4 (07)
  • [10] Buprenorphine: how to use it right
    Johnson, RE
    Strain, EC
    Amass, L
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2003, 70 : S59 - S77